Company intelligence / Profile preview

NextWave Pharmaceuticals

Cupertino, California, United Statesnextwavepharma.in ↗

Ownership: Private
Employees: ~75
Development stage: Commercial

Overview

NextWave Pharmaceuticals developed unique extended-release liquid and chewable formulations for CNS indications. Its lead product, Quillivant XR™—the first once-daily liquid methylphenidate for ADHD—was FDA-approved in 2012. The company also commercialized Nexiclon XR for hypertension. After its acquisition by Pfizer in 2012, key ADHD assets were later acquired by Tris Pharma in 2018.

Therapeutic areas: PsychiatryCardiovascularNeurology
Modalities: Small moleculesExtended-release formulations
Industry: Biotech

Drug pipeline

2 assets

clonidine

Commercial

Indications: Hypertension

1 more asset in the full pipeline.

Request access →

Partnerships

Tris Pharma – co-development/manufacturing partner using proprietary OralXR+/LiquiXR platforms.

Beyond the preview

Go deeper on NextWave Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NextWave Pharmaceuticals.

Explore the full profile